Navigation Links
PAREXEL Expert to Address Value of Incorporating Asia Into Global Clinical Development at BioMedical Asia 2009

BOSTON, March 12 /PRNewswire-FirstCall/ -- Albert Liou, Corporate Vice President and General Manager, Asia/Pacific Region at PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, will present "The True Value of Incorporating Asia into a Global Clinical Development Strategy" at the BioMedical Asia 2009 conference, to be held March 16 - 19, 2009 at the Suntec Singapore International Convention & Exhibition Centre in Singapore. Mr. Liou will discuss how biopharmaceutical companies can further expedite and improve the efficiency of studies in the Asia/Pacific region. He will also address the pros and cons of conducting clinical trials in Asia, specifically in China, Japan, South Korea and Taiwan. PAREXEL's presentation takes place on Wednesday, March 18 at 11:05 a.m. as part of the Clinical Operations and Partnering Track.

With 15 locations throughout the Asia/Pacific region, including an office in Singapore, PAREXEL helps clients address key challenges in conducting studies in the Asia/Pacific region and globally, including accessing diverse patient populations, navigating regulatory issues, identifying investigators, and ensuring data quality. PAREXEL has had a long-term commitment to providing a high level of standardization and quality clinical development services the Asia/Pacific region. For over 25 years, PAREXEL has been a proven and committed partner to pharmaceutical, biotechnology, and medical device companies looking to bring innovative new products to market. PAREXEL has extensive experience in providing comprehensive worldwide services to companies of all sizes. With deep expertise and capabilities in consulting, clinical research, eClinical technologies, and medical communications, PAREXEL has helped drive the success of thousands of its clients' development programs, and has assisted clients in getting their products to patients in need.

PAREXEL is a sponsor of the BioMedical Asia 2009 conference. Attendees at the conference can visit PAREXEL experts at Booth B01 in the exhibit hall to discuss PAREXEL's capabilities to assist biopharmaceutical companies with global clinical development programs including Asia, and with multi-national trials in the Asia/Pacific region.

For more information about PAREXEL's capabilities in Asia and other emerging regions visit More information about BioMedical Asia 2009 can be found at

About PAREXEL International PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 51 countries around the world, and has over 9,250 employees. For more information about PAREXEL International visit

This release contains "forward-looking" statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "intends," "appears," "estimates," "projects," "targets," and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent restructurings; the loss, modification, or delay of contracts which would, among other things, adversely impact the Company's recognition of revenue included in backlog; the Company's dependence on certain industries and clients; the Company's ability to win new business, manage growth and costs, and attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business, including, but not limited to, the successful business integration and anticipated synergy achievements in connection with the ClinPhone acquisition; the impact on the Company's business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended December 31, 2008 as filed with the SEC on February 9, 2009, which "Risk Factors" discussion is incorporated by reference in this press release. The forward-looking statements included in this press release represent the Company's estimates as of the date of this release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company's estimates or views as of any date subsequent to the date of this press release.

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.

    Jennifer Baird, Senior Director of Public Relations
    PAREXEL International
    Tel: +781-434-4409

    Rebecca Passo
    SHIFT Communications
    Tel: +617-779-1817

SOURCE PAREXEL International Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL International to Present at Thomas Weisel Partners Healthcare Conference
2. Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe
3. PAREXEL International Completes Acquisition of APEX International Clinical Research Co., Ltd.
4. PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors
5. PAREXEL Announces Date of First Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. PAREXEL Reports First Quarter Fiscal Year 2008 Financial Results
7. PAREXEL Appoints Charles A. Stevens as Vice President/General Manager of Health Policy and Strategic Reimbursement and Strengthens Capabilities
8. PAREXEL Announces Date of Second Quarter Fiscal Year 2008 Earnings Release and Conference Call
9. PAREXEL Names Biopharmaceutical Industry Executive Eduard E. Holdener to Board of Directors
10. PAREXEL Reports Second Quarter Fiscal Year 2008 Financial Results
11. PAREXEL International Announces 2-For-1 Stock Split
Post Your Comments:
(Date:10/13/2015)... ... October 13, 2015 , ... SonaCare Medical, LLC, a ... it received de novo clearance from the U.S. Food and Drug Administration (FDA) ... prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to ...
(Date:10/12/2015)... and BRUSSELS , Oct. 12, 2015 /PRNewswire/ ... today presented additional findings from an exploratory sub-study of the ... were presented today in an oral plenary session at the ... Meeting in Seattle . 2 ... The small exploratory sub-study data showed that, at month ...
(Date:10/12/2015)... Oct. 12, 2015  Rebiotix Inc. today announced ... designated its lead Microbiota Restoration Therapy (MRT) RBX2660 ... recurrent Clostridium difficile (C diff) infection, ... causes 29,000 deaths in the U.S. annually. 1 ... that was founded to revolutionize the treatment of ...
(Date:10/12/2015)... 2015  Patara Pharma, a clinical-stage biotechnology company ... and conditions, today announced the closing of a ... with the close of its sale of preferred ... Security Agreement with Silicon Valley Bank whereby the ... will use the funds from the financing to ...
Breaking Biology Technology:
(Date:10/6/2015)... , Oct. 6, 2015 Track Group, Inc. ... that it has signed a contract with the Virginia ... the full range of sentences under the Department,s oversight. ... the Americas. "This contract with the Virginia DOC will ... US and advances our position as a trusted leader ...
(Date:10/5/2015)... October 5, 2015 ... for NXT-ID, Inc. (NASDAQ: NXTD ), a biometric ... --> ) releases the ... NXTD ), a biometric authentication company focused on ... Technology Group ( ) releases the ...
(Date:10/1/2015)... Oct. 1, 2015  Biometrics includes diverse set ... body characteristics, such as fingerprints, eye retinas, facial ... of biometrics technology has been constantly increasing in ... five years. In addition to the most prominent ... recognition, other means of biometric authentication are rapidly ...
Breaking Biology News(10 mins):